CMA Launches Anti-Competition Investigation into AstraZeneca’s Alexion Acquisition

Article

CMA has launched an anti-competition investigation into AstraZeneca’s $39-billion acquisition of Alexion Pharmaceuticals.

On May 25, 2021, the United Kingdom’s Competition and Markets Authority (CMA) launched an anti-competition investigation into AstraZeneca’s $39-billion acquisition of Alexion Pharmaceuticals.

“[CMA] is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services,” CMA said in a statement.

CMA is currently accepting written comments regarding the December 2020 transaction until June 3, 2021.

Source: CMA

Recent Videos
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Behind the Headlines, Episode 10
Related Content